SCHEMBL6032369

SCHEMBL6032369

O=c1nc(-c2cccs2)oc2sccc12

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 9/20 0.54
▸ HPGD P15428 5/20 0.54
▸ SMN1; SMN2 Q16637 4/20 0.54
▸ MEN1 O00255 3/20 0.54
▸ KMT2A Q03164 3/20 0.54
▸ F2 P00734 1/20 0.54
▸ KDM4E B2RXH2 9/20 0.48
▸ CYP1A2 P05177 2/20 0.48
▸ CYP2C19 P33261 1/20 0.48
▸ HSD17B10 Q99714 4/20 0.47
▸ CASP1 P29466 2/20 0.47
▸ MAPK1 P28482 1/20 0.46
▸ POLB P06746 1/20 0.46
▸ GAA P10253 3/20 0.44
▸ VDR P11473 1/20 0.44
▸ NPSR1 Q6W5P4 1/20 0.44
▸ MAPT P10636 3/20 0.42
▸ NPC1 O15118 1/20 0.42
▸ TP53 P04637 1/20 0.42
▸ RAB9A P51151 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL915809 0.81 ALDH1A1 (0.61) ALDH1A1HPGDSMN1; SMN2MEN1KMT2A
SCHEMBL914639 0.76 ALDH1A1 (0.64) ALDH1A1HPGDSMN1; SMN2MEN1KMT2A
SCHEMBL914501 0.74 ALDH1A1 (0.64) ALDH1A1HPGDSMN1; SMN2MEN1KMT2A
SCHEMBL4187104 0.73 MAPT (0.55) ALDH1A1HPGDSMN1; SMN2MEN1KMT2A
SCHEMBL913374 0.70 ALDH1A1 (1.00) ALDH1A1HPGDSMN1; SMN2MEN1KMT2A
SCHEMBL1129179 0.68 KDM4E (0.65) ALDH1A1HPGDSMN1; SMN2MEN1KMT2A
SCHEMBL7396348 0.67 ALDH1A1 (0.63) ALDH1A1HPGDSMN1; SMN2MEN1KMT2A
SCHEMBL13762461 0.67 KDM4E (0.70) ALDH1A1HPGDSMN1; SMN2MEN1KMT2A
SCHEMBL7387892 0.66 ALDH1A1 (0.70) ALDH1A1HPGDSMN1; SMN2MEN1KMT2A
SCHEMBL915806 0.66 HSD17B10 (0.67) ALDH1A1HPGDSMN1; SMN2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1631295-A2 USE OF FUSED HETEROCYCLIC COMPOUNDS AS SCCE INHIBITORS FOR THE TREATMENT OF SKIN CONDITIONS OR CANCER Arexis AB (SE) 2006-03-08 — — EP disclosed
WO-2004108139-A2 USE OF FUSED HETEROCYCLIC COMPOUNDS AS SCCE INHIBITORS FOR THE TREATMENT OF SKIN CONDITIONS OR CANCER AREXIS AB (SE) 2004-12-16 — — WO disclosed
Send feedback